1994
Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine
Altemus M, Swedo S, Leonard H, Richter D, Rubinow D, Potter W, Rapoport J. Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine. JAMA Psychiatry 1994, 51: 794-803. PMID: 7524463, DOI: 10.1001/archpsyc.1994.03950100042004.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing hormoneLong-term treatmentObsessive-compulsive disorderCSF levelsHomovanillic acidCSF monoamine metabolite levelsCentral administrationCerebrospinal fluid levelsSignificant decreaseCSF homovanillic acidMonoamine metabolite levelsCerebrospinal fluid neurochemistryCSF oxytocin levelsOpposite behavioral effectsPharmacologic treatmentSomatostatin levelsMonoamine metabolitesPathophysiologic processesFluid levelsBehavioral effectsOxytocin levelsClomipramine hydrochlorideMetabolite levelsDisordersVasopressin
1993
Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers
De Bellis M, Geracioti T, Altemus M, Kling M. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biological Psychiatry 1993, 33: 636-641. PMID: 7687151, DOI: 10.1016/0006-3223(93)90103-k.Peer-Reviewed Original ResearchConceptsMedication-free patientsHealthy volunteersFluoxetine treatmentHomovanillic acidMean Hamilton Depression Rating Scale scoreHamilton Depression Rating Scale scoresDepression Rating Scale scoresPmol/CSF monoamine metabolite levelsFluoxetine-treated patientsCerebrospinal fluid levelsMajor depressive disorderMonoamine metabolite levelsRating Scale scoresCerebrospinal fluid monoamineHVA/5-HIAA ratioCSF HVA/5-HIAA ratioDepressive disorderMajor depressionScale scoreFluid levelsPatientsDSM-IIIMetabolite levelsVolunteers